menu
    • menu
    [{"orgOrder":0,"company":"Jiangsu Simcere Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Iguratimod","moa":"E3 ubiquitin ligase TRAF3IP2 | Cyclooxygenase-2 | Macrophage migration inhibitory factor","graph1":"Immunology","graph2":"Phase II","graph3":"Jiangsu Simcere Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Jiangsu Simcere Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Jiangsu Simcere Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Nanfang Hospital, Southern Medical University","sponsor":"Jiangsu Simcere Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Iguratimod","moa":"E3 ubiquitin ligase TRAF3IP2 | Cyclooxygenase-2 | Macrophage migration inhibitory factor","graph1":"Immunology","graph2":"Phase IV","graph3":"Nanfang Hospital, Southern Medical University","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nanfang Hospital, Southern Medical University \/ Jiangsu Simcere Pharmaceutical","highestDevelopmentStatusID":"11","companyTruncated":"Nanfang Hospital, Southern Medical University \/ Jiangsu Simcere Pharmaceutical"}]

    Find Clinical Drug Pipeline Developments & Deals for Iguratimod

    Menu

    Iguratimod

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Nanfang Hospital, Southern Medical University

                            Country arrow
                            CPHI Shenzhen
                            Not Confirmed

                            Nanfang Hospital, Southern Medical University

                            Country arrow
                            CPHI Shenzhen
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Iguratimod

                            Therapeutic Area : Immunology

                            Study Phase : Phase IV

                            Sponsor : Jiangsu Simcere Pharmaceutical

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Iguratimod Combined With Tofacitinib in the Treatment of Rheumatoid Arthritis

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            April 07, 2023

                            Lead Product(s) : Iguratimod

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase IV

                            Sponsor : Jiangsu Simcere Pharmaceutical

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Jiangsu Simcere Pharmaceutical

                            China arrow
                            CPHI Shenzhen
                            Not Confirmed

                            Jiangsu Simcere Pharmaceutical

                            China arrow
                            CPHI Shenzhen
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Iguratimod

                            Therapeutic Area : Immunology

                            Study Phase : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study to Evaluate the Efficacy and Safety of Iguratimod Compared to Placebo in Patients With Active Primary ...

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            April 05, 2021

                            Lead Product(s) : Iguratimod

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Jiangsu Simcere Pharmaceutical

                            China arrow
                            CPHI Shenzhen
                            Not Confirmed

                            Jiangsu Simcere Pharmaceutical

                            China arrow
                            CPHI Shenzhen
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Iguratimod

                            Therapeutic Area : Immunology

                            Study Phase : Phase IV

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Study of Iguratimod Plus Methotrexate Compared to Leflunomid Plus Methotrexate in Patients With Rheumatoid Art...

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            October 27, 2014

                            Lead Product(s) : Iguratimod

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase IV

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Jiangsu Simcere Pharmaceutical

                            China arrow
                            CPHI Shenzhen
                            Not Confirmed

                            Jiangsu Simcere Pharmaceutical

                            China arrow
                            CPHI Shenzhen
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Iguratimod

                            Therapeutic Area : Immunology

                            Study Phase : Phase IV

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Effectiveness of Iguratimod Versus Placebo to Treat Early Rheumatoid Arthritis on MRI

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            July 08, 2013

                            Lead Product(s) : Iguratimod

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase IV

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Jiangsu Simcere Pharmaceutical

                            China arrow
                            CPHI Shenzhen
                            Not Confirmed

                            Jiangsu Simcere Pharmaceutical

                            China arrow
                            CPHI Shenzhen
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Iguratimod

                            Therapeutic Area : Immunology

                            Study Phase : Phase IV

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study of Iguratimod in Patients With Active Rheumatoid Arthritis

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            March 15, 2012

                            Lead Product(s) : Iguratimod

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase IV

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Jiangsu Simcere Pharmaceutical

                            China arrow
                            CPHI Shenzhen
                            Not Confirmed

                            Jiangsu Simcere Pharmaceutical

                            China arrow
                            CPHI Shenzhen
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Iguratimod

                            Therapeutic Area : Immunology

                            Study Phase : Phase IV

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Long-term Efficacy of Iguratimod Alone or Iguratimod in Combination With Methotrexate in Patients With Rheumat...

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            March 08, 2012

                            Lead Product(s) : Iguratimod

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase IV

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth